{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Impairments",
    "query": {
      "condition": "Renal Impairments"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 334,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Impairments&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:47:50.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02431481",
      "title": "Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Normal Renal Function",
        "Impaired Renal Function"
      ],
      "interventions": [
        {
          "name": "LEE011",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-10-23",
      "completion_date": "2018-05-11",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431481"
    },
    {
      "nct_id": "NCT00445302",
      "title": "Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 23,
      "start_date": "2006-01",
      "completion_date": "2007-08",
      "has_results": true,
      "last_update_posted_date": "2014-03-13",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 3,
      "location_summary": "Santa Ana, California • Saint Paul, Minnesota • Omaha, Nebraska",
      "locations": [
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445302"
    },
    {
      "nct_id": "NCT00634049",
      "title": "Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aspergillosis",
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "isavuconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2008-04-22",
      "completion_date": "2016-05-05",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00634049"
    },
    {
      "nct_id": "NCT02260193",
      "title": "16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "AKB-6548",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 94,
      "start_date": "2014-09-10",
      "completion_date": "2015-07-22",
      "has_results": true,
      "last_update_posted_date": "2022-07-01",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 16,
      "location_summary": "El Granada, California • Long Beach, California • San Dimas, California + 13 more",
      "locations": [
        {
          "city": "El Granada",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Santa Clarita",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02260193"
    },
    {
      "nct_id": "NCT05601128",
      "title": "A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection",
        "HIV Infections",
        "HIV I Infection"
      ],
      "interventions": [
        {
          "name": "CAB + RPV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 12,
      "start_date": "2023-01-01",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05601128"
    },
    {
      "nct_id": "NCT03506854",
      "title": "Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "ISIS 681257",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akcea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2018-03-20",
      "completion_date": "2018-10-11",
      "has_results": false,
      "last_update_posted_date": "2019-05-22",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506854"
    },
    {
      "nct_id": "NCT02917057",
      "title": "Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "exenatide once weekly",
          "type": "DRUG"
        },
        {
          "name": "basal insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6024,
      "start_date": "2015-08-01",
      "completion_date": "2015-08-01",
      "has_results": false,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02917057"
    },
    {
      "nct_id": "NCT07154901",
      "title": "Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "Opemalirsen (AZD2373)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2025-08-18",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07154901"
    },
    {
      "nct_id": "NCT01555008",
      "title": "Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "LX4211",
          "type": "DRUG"
        },
        {
          "name": "LX4211 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2012-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-09",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01555008"
    },
    {
      "nct_id": "NCT07348237",
      "title": "A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Failure",
        "End-Stage Renal Disease",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "MK-2828",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "24 Years to 85 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-03-02",
      "completion_date": "2026-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-05-22T07:47:50.818Z",
      "location_count": 3,
      "location_summary": "Miami Lakes, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348237"
    }
  ]
}